NASDAQ: TRVNTrevena Inc Stock
$0.39-0.02 (-4.88%)
Updated Apr 26, 2024
TRVN Price
$0.39
Fair Value Price
N/A
Market Cap
$7.16M
52 Week Low
$0.30
52 Week High
$3.28
P/E
-0.12x
P/B
-0.94x
P/S
2.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.13M
Earnings
-$40.29M
Gross Margin
46.6%
Operating Margin
-1,162.46%
Profit Margin
-1,289.2%
Debt to Equity
-6.3
Operating Cash Flow
-$33M
Beta
0.75
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TRVN Overview
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRVN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRVN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TRVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TRVN due diligence checks available for Premium users.
Be the first to know about important TRVN news, forecast changes, insider trades & much more!
TRVN News
Valuation
TRVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
14.88x
Market
41.14x
TRVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.94x
Industry
5.85x
TRVN's financial health
Profit margin
Revenue
-$82.0k
Net Income
-$16.5M
Profit Margin
20,156.1%
TRVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TRVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$40.6M
Liabilities
$48.3M
Debt to equity
-6.3
TRVN's short-term assets ($35.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRVN's long-term liabilities ($40.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$21.0k
Financing
$4.0M
TRVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRVN vs Biotech Stocks
Trevena Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.